Rajasekhar N.V.S. Suragani

Bristol-Myers Squibb (Sweden) — Sweden

Medicine · Health Sciences

11h-index1.2kcitations63works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(22), Myeloproliferative Neoplasms: Diagnosis and Treatment(21), Hemoglobinopathies and Related Disorders(20), Erythrocyte Function and Pathophysiology(12), RNA regulation and disease(10)

Publications63 total

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial
Blood·2025Open Access
Luspatercept reduces cardiac stress and improves cardiac function in a TET2-deficient mouse model with features of heart failure with preserved ejection fraction: Evidence from phase 3 commands trial and pre-clinical studies
Blood·2025
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes
Journal of Clinical Investigation·2025· 2 citedOpen Access
Clonal Haematopoiesis with <i>TP53</i> Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
Blood·2024Open Access
Impact of Mutational Landscape and Biomarkers on Response of Luspatercept (ACE-536) Treatment of Anemia in Non-Transfusion Dependent IPSS-R Lower Risk MDS Japanese Subjects (ACE-536-MDS-003- a Ph2 single-arm study)
Blood·2024· 1 cited
Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease
Blood·2024· 1 citedOpen Access
Role of Clonal Hematopoiesis (CH) in Lymphoma: Prevalence and Clinical Impact in Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Blood·2024Open Access
DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation
Blood·2024Open Access
Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways
Blood·2024· 2 cited
3020 – SPLICING OF A MASTER ERYTHROID TRANSCRIPTION FACTOR GOVERNS THERAPEUTIC TARGETING OF ANEMIA IN MDS
Experimental Hematology·2024
Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A Subgroup Analysis from the Phase 3 COMMANDS Trial
Blood·2023· 3 cited
Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study
Blood·2023· 1 cited
Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study
Blood·2023· 8 cited
Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial
Blood·2023· 1 cited
Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial
Blood·2023· 1 citedOpen Access
An Integrated Single Cell Immunogenomic Atlas Reveals Pathways of Clonal Expansion, Inflammation and Dyserythropoiesis in Low and High-Risk Clonal Haematopoiesis
Blood·2023Open Access
POSTER: MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase III COMMANDS Study
Clinical Lymphoma Myeloma & Leukemia·2023
MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase III COMMANDS Study
Clinical Lymphoma Myeloma & Leukemia·2023
P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
HemaSphere·2023· 5 citedOpen Access
P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
HemaSphere·2023· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Anita K. Gandhi(16), Ravindra Kumar(15), R. Scott Pearsall(14), Sadanand Vodala(10), Robert Li(9), Sheida Hayati(9), Uwe Platzbecker(8), Asya V. Grinberg(7), Srinivas Aluri(7), Aarif Ahsan(7), Sharon M Cawley(6), Dianne Sako(6), Amit Verma(6), Sijin Liu(5), Jane-Jane Chen(5), Pedro A. Martinez(5), Daniel L. Menezes(5), Mark J. Alexander(4), Aaron W. Mulivor(4), Stefano Rivella(4)